Seirei Hospice

Shizuoka-shi, Japan

Seirei Hospice

Shizuoka-shi, Japan

Time filter

Source Type

Yokomichi N.,Seirei Hospice | Morita T.,Seirei Hospice | Morita T.,Seirei Mikatahara General Hospital | Nitto A.,National Cancer Center Hospital East | And 7 more authors.
Journal of Pain and Symptom Management | Year: 2015

Context The Edmonton Symptom Assessment System-revised (ESAS-r) is a brief and widely used symptom measurement tool. Objectives To validate the Japanese version of the ESAS-r in Japanese patients with cancer. Methods We assessed the internal consistency, test-retest reliability, concurrent validity, and known-group validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS-r, M. D. Anderson Symptom Inventory, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. Results Cronbach's alpha coefficient of the Japanese version of the ESAS-r was 0.87. The intraclass correlation coefficient in the test-retest examination ranged from 0.82 to 0.91 for each symptom score and was 0.90 for the total score. Pearson correlation coefficients of each ESAS-r symptom score with corresponding M. D. Anderson Symptom Inventory and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items ranged from 0.45 to 0.80. The total score of the ESAS-r was significantly higher in patients with an Eastern Cooperative Oncology Group performance status of 2-4 than in those with a performance status of 0 and 1 (P < 0.0001). Conclusion The Japanese version of the ESAS-r is a reliable and valid tool for measuring symptoms in Japanese adult patients with cancer. © 2015 American Academy of Hospice and Palliative Medicine.


PubMed | Red Cross, National Cancer Center Hospital East, Seirei Hospice, University of Alberta and 5 more.
Type: Journal Article | Journal: Journal of pain and symptom management | Year: 2015

The Edmonton Symptom Assessment System-revised (ESAS-r) is a brief and widely used symptom measurement tool.To validate the Japanese version of the ESAS-r in Japanese patients with cancer.We assessed the internal consistency, test-retest reliability, concurrent validity, and known-group validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS-r, M. D. Anderson Symptom Inventory, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30.Cronbachs alpha coefficient of the Japanese version of the ESAS-r was 0.87. The intraclass correlation coefficient in the test-retest examination ranged from 0.82 to 0.91 for each symptom score and was 0.90 for the total score. Pearson correlation coefficients of each ESAS-r symptom score with corresponding M. D. Anderson Symptom Inventory and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items ranged from 0.45 to 0.80. The total score of the ESAS-r was significantly higher in patients with an Eastern Cooperative Oncology Group performance status of 2-4 than in those with a performance status of 0 and 1 (P<0.0001).The Japanese version of the ESAS-r is a reliable and valid tool for measuring symptoms in Japanese adult patients with cancer.

Loading Seirei Hospice collaborators
Loading Seirei Hospice collaborators